William J. Chapin, MD, MSCE

O'Connor S, Seewald N, Chapin WJ, Doucette A, Blaha C, Reiss KA. Evaluation of the impact of GLP-1 receptor agonists (RAs) on stage of PDAC diagnosis: A retrospective matched cohort study. , American Society of Clinical Oncology Annual Meeting, Chicago, IL. , 44: 2026

Morris II VK, Colby S, Kopetz S, Guthrie KA, Chapin WJ, Breakstone R, Hu ZI, Fakih M, Gholami S, Gold PJ, Chiorean EG, Philip PA. SWOG S2107: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated MSS, BRAFV600E metastatic colorectal cancer (mCRC). , American Society of Clinical Oncology Annual Meeting, Chicago, IL. , 44: 2026

Chapin WJ, Cenou N, Delman D, Eads JR, Manley M, Reiss KA, Sackey M, Teitelbaum UR, Walsh J, Beatty GL, O'Hara MH. Phase II trial of pembrolizumab in combination with odetiglucan for patients with metastatic colorectal adenocarcinoma with liver-predominant disease. , American Society of Clinical Oncology Annual Meeting, Chicago, IL. , 44: 2026

Boursi B, Stemmer A, Chapin WJ, Shacham-Shmueli E, Kopetz S, Andre T, Overman MJ, Pietrantonio F, Margalit O. Durable responses to immunotherapy in dMMR/MSI-H metastatic colorectal cancer patients with poor performance status. , American Society of Clinical Oncology Annual Gastrointestinal Meeting, San Francisco, CA. : 2026

Kim RD, Saeed A, Chapin WJ, Kim K, Iyer R, Martin II RC, Grothey A, Gadde S, Feun LG, Gabayan A, Saenger YM, Abdelrahim M, Govada N, Xie B, Cho M, Burgoyne A. A multicenter, open-label study of RP2 oncolytic immunotherapy expressing anti–CTLA-4 in combination with second-line atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (HCC) or in combination with first-line durvalumab in advanced biliary tract cancer (BTC). , American Society of Clinical Oncology Annual Gastrointestinal Meeting, San Francisco, CA.: 2026

Boursi B, Kolkey ZL, Reiss KA, O'Hara MH, Chapin WJ. Comparative effectiveness of oxaliplatin or irinotecan rechallenge vs standard third-line therapies in patients with metastatic colorectal cancer. , American Society of Clinical Oncology Annual Gastrointestinal Meeting, San Francisco, CA. : 2026

Lin JK, Niu J, Giordano SH, Li P, Snyder RA, Liao K, Li M, Aparicio A, Chapin W, Zhang J, Xiang J, Perera N, Pain D, Guerra CE, Doshi JA. Racial and Ethnic Disparities Along the Treatment Cascade Among Medicare Fee-for-Service Beneficiaries With Metastatic Breast, Colorectal, Lung, and Prostate Cancers , J Clin Oncol: 2025

Swami N, Hwang WT, Mamtani R, O'Hara MH, Chapin WJ. Second-Line Treatment Strategies for Right-Sided, RAS/RAF Wild-Type Colorectal Cancer , JAMA Netw Open, 8: 2025,e2515087

Swami N, Hwang WT, O’Hara MH, Chapin WJ. Real-world evaluation of a “hyperselection” predictive biomarker for anti-EGFR therapy benefit in patients with RAS/RAF wild-type, MMRp/MSS mCRC , J Clin Oncol, 43(16): 2025

Nishwant Swami, Wei-Ting Hwang, Ronac Mamtani, Mark O'Hara, William Chapin Real-world survival comparison of second-line treatment strategies for patients with RAS/RAF wild-type, right-sided metastatic colorectal cancer. , Journal of Clinical Oncology, 43(4_suppl): 2025,73